8月20日早间和黄医药在港交所公告沃瑞沙和泰瑞沙的联合疗法用于一线治疗伴有表皮生长因子受体(EGFR)突变及MET过表达

智通财经
Aug 20
8月20日早间和黄医药在港交所公告沃瑞沙和泰瑞沙的联合疗法用于一线治疗伴有表皮生长因子受体(EGFR)突变及MET过表达的特定非小细胞肺癌患者的SANOVO中国III期研究已完成患者入组。该研究的最后一名患者已于2025年8月18日完成入组。SANOVO研究的顶线结果预计将于2026年下半年公布并将随即提交研究结果于适当的学术会议发表。若取得理想的结果和黄医药将启动计划向国家药监局递交新适应症上市申请。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10